Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Porphyrias constitute a group of eight hereditary metabolic diseases characterized by intermittent neuro-visceral manifestations, cutaneous lesions or by the combination of both.
Biomarker and diagnostic research for inherited porphyria has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
13 clinical trials registered, 6 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 2 PHASE3, 2 PHASE2, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07024316](https://clinicaltrials.gov/study/NCT07024316) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:05 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
PHASE1 |
Atlas Molecular Pharma |
RECRUITING |
[NCT01561157](https://clinicaltrials.gov/study/NCT01561157) | Longitudinal Study of the Porphyrias | — | The American Porphyrias Expert Collaborative | RECRUITING |
[NCT05502133](https://clinicaltrials.gov/study/NCT05502133) | Identification of Acute Intermittent Porphyria Modifying Genes | — | Icahn School of Medicine at Mount Sinai | RECRUITING |
[NCT04883905](https://clinicaltrials.gov/study/NCT04883905) | ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | — | Alnylam Pharmaceuticals | RECRUITING |
[NCT06273644](https://clinicaltrials.gov/study/NCT06273644) | Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment | NA | Nordlandssykehuset HF | RECRUITING |
186 publications have been identified in PubMed for inherited porphyria. Research spans Basic Science / Preclinical (46%), Review / Meta-Analysis (32%), and Diagnostic / Biomarker (6%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 81 | 46% |
Research summaries | 56 | 32% |
Testing and diagnosis research | 10 | 6% |
Disease patterns and progression | 10 | 6% |
Other research | 7 | 4% |
Patient case studies | 6 | 3% |
Clinical study results | 4 | 2% |
New treatment approaches | 3 | 2% |
Vizerov T (2026). [PMID: 42158594](https://pubmed.ncbi.nlm.nih.gov/42158594/). *Mol Genet Metab Rep*. [Basic Science / Preclinical]
Padda IS (2026). [PMID: 35593797](https://pubmed.ncbi.nlm.nih.gov/35593797/). *Unknown Journal*. [Gene Therapy / Novel Therapeutics]
Dyńka D (2026). [PMID: 41486865](https://pubmed.ncbi.nlm.nih.gov/41486865/). *Ann Med*. [Review / Meta-Analysis]
Di Pierro E (2026). [PMID: 41268747](https://pubmed.ncbi.nlm.nih.gov/41268747/). *J Intern Med*. [Basic Science / Preclinical]
Visser WI (2026). [PMID: 41486327](https://pubmed.ncbi.nlm.nih.gov/41486327/). *Dermatol Ther (Heidelb)*. [Review / Meta-Analysis]
Hashmi MF (2026). [PMID: 31082078](https://pubmed.ncbi.nlm.nih.gov/31082078/). *Unknown Journal*. [Epidemiology / Natural History]
Gounden V (2026). [PMID: 30726037](https://pubmed.ncbi.nlm.nih.gov/30726037/). *Unknown Journal*. [Epidemiology / Natural History]
Zurawska G (2026). [PMID: 41495467](https://pubmed.ncbi.nlm.nih.gov/41495467/). *EMBO Rep*. [Basic Science / Preclinical]
Reeves EB (2026). [PMID: 42107342](https://pubmed.ncbi.nlm.nih.gov/42107342/). *Mol Genet Metab*. [Review / Meta-Analysis]
Liu J (2026). [PMID: 41813554](https://pubmed.ncbi.nlm.nih.gov/41813554/). *Trends Endocrinol Metab*. [Review / Meta-Analysis]